Miglustat

證據等級: L5

預測適應症: 10 個

Miglustat: From Gaucher Disease to Tay-Sachs Disease (GM2 Gangliosidosis)

One-Sentence Summary

Miglustat is an oral small-molecule glucosylceramide synthase inhibitor originally developed and approved in the EU for type 1 Gaucher disease as a substrate reduction therapy (SRT). Among 10 TxGNN-predicted indications, Tay-Sachs disease (GM2 gangliosidosis) is the only one with actual supporting evidence — 5 clinical trials and 20 publications, including one completed randomized controlled trial. The remaining 9 candidates are model-prediction-only with no clinical or literature support.

Note: this drug generated 10 TxGNN-predicted indications in the evidence pack; 9 of them (autosomal ichthyosis, cholesteryl ester storage disease, Krabbe disease, metachromatic leukodystrophy, Wolman disease, prosaposin deficiency encephalopathy, benign adrenal neoplasm, X-linked ichthyosis, FA2H-associated neurodegeneration) have no clinical trials or literature evidence (evidence level L5, decision stage S0, recommendation Hold) and are not detailed further in this report. This report focuses on the one candidate with real evidentiary support.

Quick Overview

Item	Content
Original Indication	Type 1 Gaucher disease (per literature; miglustat/Zavesca received EU approval Nov 2002)
Predicted New Indication	Tay-Sachs disease (GM2 Gangliosidosis)
TxGNN Prediction Score	99.75%
Evidence Level	L2
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the structured drug record (Data Gap, DG002). Based on the literature captured in this evidence pack (PMID 12808890), miglustat is an orally administered glucosylceramide glucosyltransferase (glucosylceramide synthase) inhibitor — a substrate reduction therapy (SRT) — originally licensed for type 1 Gaucher disease, where it slows the rate of glycosphingolipid synthesis to a level the residual mutant enzyme can clear.

GM2 gangliosidosis (Tay-Sachs and Sandhoff disease) is caused by β-hexosaminidase deficiency leading to accumulation of GM2 ganglioside, a glycosphingolipid synthesized downstream of the same glucosylceramide pathway that miglustat inhibits. This is mechanistically the same SRT rationale already validated in Gaucher disease and Niemann-Pick type C.

Foundational animal work (PMID 9103204, Science 1997) showed that NB-DNJ (miglustat's precursor compound) prevented GM2 ganglioside accumulation and lysosomal storage in a Tay-Sachs mouse model, and this was extended to other mouse models of glycosphingolipidoses (PMID 12803928). This preclinical rationale translated into a completed 12-month randomized controlled trial in late-onset Tay-Sachs disease (PMID 19346952), giving this prediction a stronger evidentiary basis than any of the other 9 TxGNN candidates for this drug.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00418847	Phase 2	Completed	5	Pharmacokinetics/tolerability of single and multiple oral doses in juvenile GM2 gangliosidosis
NCT00672022	Phase 3	Completed	10	PK/safety/tolerability in infantile-onset GM2 gangliosidosis (classical Tay-Sachs and infantile Sandhoff); miglustat inhibits GM2 ganglioside formation, may reduce/delay symptom onset
NCT03822013	Phase 3	Terminated	30	Survey of miglustat effects on neurological/systemic symptoms in infantile Sandhoff/Tay-Sachs; infantile forms are often lethal, management largely supportive
NCT02030015	Phase 4	Terminated	16	Miglustat + ketogenic diet (Syner-G) combination for infantile/juvenile gangliosidoses, hypothesized synergy on survival and neurodevelopmental outcomes
NCT07399704	Phase 2	Recruiting	21	Long-term safety/PK/efficacy of nizubaglustat in GM2 gangliosidosis/NPC-C patients, including a cohort transitioning from prior miglustat therapy

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19346952	2009	RCT	Genetics in Medicine	12-month randomized controlled study (plus 24-month extension) evaluating safety and efficacy of miglustat in GM2 gangliosidosis
37209042	2023	Systematic Review	European Journal of Neurology	Systematic review of miglustat efficacy/safety in GM2 gangliosidosis, noting prior inconsistent results
18618288	2008	Cohort (pilot)	Journal of Inherited Metabolic Disease	Neurocognitive testing pilot in late-onset Tay-Sachs disease as a candidate outcome measure for therapeutic trials
32867370	2020	Review	Int J Molecular Sciences	Overview of GM2 gangliosidoses clinical features, pathophysiology, and current therapies
30524313	2018	Review	Frontiers in Physiology	Review of new therapeutic approaches for Tay-Sachs disease
16434676	2006	Case series/Cohort	Neurology	SRT with miglustat in two infantile Tay-Sachs patients; could not arrest neurologic deterioration but achieved measurable CSF drug levels and prevented macrocephaly
12808890	2003	—	Curr Opin Investig Drugs	Miglustat licensed for type 1 Gaucher disease (EU approval Nov 2002); also in development for Tay-Sachs, Fabry, and Niemann-Pick type C
9103204	1997	—	Science	Foundational mouse study: NB-DNJ (miglustat precursor) prevented GM2 accumulation and storage-neuron pathology in a Tay-Sachs mouse model
12803928	2003	—	Phil Trans R Soc Lond B	SRT efficacy shown across mouse models of Tay-Sachs, Sandhoff, and Fabry disease
30743792	2009	—	Expert Rev Endocrinol Metab	Review of SRT with miglustat for glycosphingolipid storage disorders affecting the brain

Finland Market Information

Miglustat is currently not marketed in Finland — no marketing authorizations are on record (0 licenses).

Safety Considerations

Please refer to the package insert for safety information. (TFDA/Fimea package-insert warnings, contraindications, and drug interaction data are flagged as a blocking data gap — see Conclusion below.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The Tay-Sachs/GM2 gangliosidosis candidate has genuine supporting evidence — one completed RCT (PMID 19346952) plus multiple completed Phase 2/3 PK and safety trials — built on a mechanistically sound SRT rationale already validated in Gaucher disease. However, a Phase 3 trial (NCT03822013) and a Phase 4 combination trial (NCT02030015) were both terminated, and case-series data (PMID 16434676) show SRT could not halt neurologic deterioration in infantile-onset disease, suggesting benefit is more established in late/juvenile-onset than in the rapidly fatal infantile form. The other 9 TxGNN-predicted indications for this drug remain L5/Hold with no clinical or literature support and should not be pursued at this time.

To proceed, the following is needed:

DrugBank MOA data (DG002) to confirm mechanistic pathway details
TFDA/Fimea package insert warnings and contraindications (DG001, blocking — required before S1 safety review)
Reasons for termination of NCT03822013 and NCT02030015
Subgroup efficacy data stratified by disease onset (infantile vs. juvenile vs. late-onset), since evidence strength differs markedly between these populations
DDI data (currently not found in query)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.